BioMimetic Therapeutics, Inc. has announced that it is selling the manufacturing rights for GEM 21S -- its grafting material for bone and periodontal regeneration -- to
Luitpold Pharmaceuticals, Inc. BioMimetic will receive $40 million plus royalties.